Andreas H. Rossevold
Oslo, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy.
Journal: Molecular oncology
Published: February 20, 2025
High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis.
Journal: Communications medicine
Published: October 20, 2024
Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer.
Journal: Molecular oncology
Published: May 05, 2024
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials.
Journal: Molecular oncology
Published: February 14, 2024
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.
Journal: Journal for immunotherapy of cancer
Published: December 27, 2023
Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation.
Journal: NPJ breast cancer
Published: September 08, 2023
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.
Journal: Nature medicine
Published: October 17, 2022
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.
Journal: Journal of translational medicine
Published: April 27, 2020
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment.
Journal: Nature communications
Published: December 11, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026